131827 20260120144241.0 doi 10.1016/j.msard.2021.102995 sideral 137007 ART-2021-137007 eng Garcés Redondo, Moisés Universidad de Zaragoza (orcid)0000-0002-1756-5492 Response to hepatitis B vaccine in patients with multiple sclerosis: preliminary data 2021 Background Studies in different autoimmune pathologies report a lower response rate (immunogenicity) to vaccinations than in the general population. Our objective is to analyze the immunogenicity of the vaccine against hepatitis B virus (HBV) in patients with multiple sclerosis (MS). Methods In a single prospective cohort of MS patients with negative HBV serology, hepatitis B (rDNA) B vaccine was administered at 0, 1 and 6 months. Immunogenicity was analyzed by the determination of antibodies to surface antigens of HBV. We considered a patient as a responder if antibodies level was higher than 10 IU/L. Posterior analysis of immunogenicity was conducted by demographic variables (e.g. MS phenotype, EDSS) and use of disease-modifying drugs (DMTs). Results Vaccination study of 251 patients: 160 of them were sero-negative (63.7%). Patients vaccinated: 99. Overall response: 74.1%. No significant relationship by sex (female 77.6% responders, male 68.8%) and MS phenotype (relapsing forms 74.3% responders, secondary progressive 50%). Variables associated with significantly lower immunogenicity were: age (>55 years), EDSS score (median: non-responders=3.0, responders=1.0), number of relapses and treatment with fingolimod (28.6% responders, n=7). Anti-CD20 therapies showed lower vaccine response (50%), but were not very represented in our sample (n=2). Immunogenicity with other DMTs: interferon/glatiramer 69.6% (n=23), teriflunomide 71.4% (n=14), dimethylfumarate 92.3% (n=13), natalizumab 100% (n=7). Conclusion The overall immunogenicity of our sample is lower than that reported in the general population (74 vs >86%), as in other autoimmune diseases. Preliminary data show a lower immunogenicity with older age, higher EDSS score, number of relapses and fingolimod use. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 4.808 2021 CLINICAL NEUROLOGY 64 / 212 = 0.302 2021 Q2 T1 1.006 2021 Neurology 2021 Q1 Medicine (miscellaneous) 2021 Q1 5.0 2021 info:eu-repo/semantics/conferenceObject info:eu-repo/semantics/publishedVersion Val Lafaja, Alodia de Universidad de Zaragoza Atienza Ayala, Saida Universidad de Zaragoza (orcid)0000-0003-0715-2843 Garcés Antón, Esther Universidad de Zaragoza Marín Gracia, Carmen Marta (orcid)0000-0001-6839-7751 Román Calderón, Francisco (orcid)0000-0002-9233-1960 López Mendoza, Héctor (orcid)0000-0002-4528-1921 Chaure Pardos, Armando Hernández García, Ignacio (orcid)0000-0003-1334-6783 Íñiguez Martínez, Cristina Universidad de Zaragoza (orcid)0000-0002-2711-066X 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 51 (2021), 102995 [2 pp.] Mult. scler. relat. disord. Multiple Sclerosis and Related Disorders 2211-0348 126012 http://zaguan.unizar.es/record/131827/files/texto_completo.pdf Versión publicada 3394767 http://zaguan.unizar.es/record/131827/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:131827 articulos driver 2026-01-20-14:41:28 ARTICLE